Semaglutide for Post-Smoking Cessation Weight Management

PHASE2RecruitingINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

August 1, 2026

Conditions
ObesityOverweightCigarette Smoking
Interventions
DRUG

semaglutide 2.4mg

Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached

DRUG

Placebo

Non-active medication, self-administered

DRUG

Nicotine Replacement Therapy (NRT, nicotine patch)

Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

BEHAVIORAL

Brief Smoking Cessation Counseling

Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.

Trial Locations (2)

77054

RECRUITING

The University of Texas Health Science Center at Houston, Houston

78723

RECRUITING

The University of Texas at Austin, Austin

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT06173778 - Semaglutide for Post-Smoking Cessation Weight Management | Biotech Hunter | Biotech Hunter